Abstract: OBJECTIVE: This study was undertaken to isolate and characterize multipotent mesenchymal stem cells from term human placenta (placenta-derived mesenchymal stem cells, PD-MSCs). STUDY DESIGN: Sequential enzymatic digestion was used to isolate PD-MSCs in which trypsin removes the trophoblast layer, followed by collagenase treatment of remaining placental tissue. Karyotype, phenotype, growth kinetics, and differentiability of PD-MSC isolates from collagenase digests were analyzed. RE-SULTS: PD-MSC isolation was successful in 14 of 17 cases. Karyotyping of PD-MSC isolates from deliveries with a male fetus revealed that these cells are of maternal origin. Flow cytometry and immunocytochemistry confirmed the mesenchymal stem cell phenotype. Proliferation rates of PD-MSCs remained constantly high up to passage 20. These cells could be differentiated toward mesodermal lineage in vitro up to passage 20. Nonconfluent culture was critical to maintain the MSC stemness during long-term culture. CONCLUSION: Term placenta constitutes a rich, very reliable source of maternal mesenchymal stem cells that remain differentiable, even at high passage numbers. 
Condensation
Sequential enzymatic digest of term human placenta effectively isolates multipotent mesenchymal stem cells of maternal origin that remain multipotent in conditions of sub confluent expansion.
Introduction
Mesenchymal stem cells (MSCs) represent an interesting cell type for research and therapy because of their ability to differentiate into mesodermal lineage cells such as osteocytes, chondrocytes, cardiac muscle, or endothelial cells 1 . In addition, they secrete large amounts of pro-angiogenic and anti-apoptotic cytokines 2 and possess remarkable immunosuppressive properties 3 . MSCs have been derived from many different organs and tissues 4 Evidence has emerged that also different parts of human placenta, umbilical cord, amniotic membrane, as well as umbilical cord blood harbor MSCs. [5] [6] [7] [8] [9] These tissues are normally discarded after birth, avoiding ethical concerns. 10 Mechanical as well as enzymatic methods for MSC isolation from different regions of human placenta of different gestational ages were reported (Table 1 , see references therein). 5, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Knowledge about vitality, karyotype, phenotype and expandability of such placenta-derived MSC isolates is a prerequisite for therapeutic application, however systematic investigations into reliability of this MSC source and phenotypic stability have not yet been attempted. Further, former reports on placenta-derived MSCs often lack information about the karyotype of the cell isolates. Here we describe enzymatic fractionation of term human placenta that allows recovery of multipotent, fibroblast-like cells, which we tentatively term as placenta-derived mesenchymal stem cells (PD-MSCs) with high fidelity. Unexpectedly, as demonstrated by genotypic analyses of cell isolates from male deliveries, the resulting isolates were of maternal, not fetal origin. Our systematic characterization of cell isolates from multiple cases showed that these cell isolates reproducibly fulfil the general definition of MSCs both by phenotypic and functional criteria. 27 We demonstrate that maternally-derived PD-MSCs can be greatly expanded, maintain they differentiation capacity and stable phenotype up to passage 20.
Materials and Methods

Placenta collection
The Ethical Committee of the District of Zurich approved the protocol (study Stv22/2006).
Following written consent, placentas were collected from 17 women donors immediately after elective caesarean section in the absence of labor, preterm rupture of membranes, chorioamnionitis, or chromosomal abnormalities. Mean maternal age was 32 years (between 28 and 39 years) and mean gestational age was 38 ±1 weeks. Mean placental weight was 573 ±113 g. Figure 1 depicts the isolation procedure. After removal of decidua and fetal membranes, approximately 30g placental tissue was minced and washed three times in physiological saline. Blood vessels and clots were removed mechanically. The minced placental tissue was subjected to sequential digests with trypsin and collagenase I. First, to remove the trophoblastic epithelial cell layer, tissue was incubated in 50mL 0.25% trypsin solution containing 80U/mL DNase I (Roche AG, Basel, Switzerland) for 1 h at 37°C. The remaining placental fragments were separated in a 250µm metal sieve from the 'trypsin cell suspension'.
Cell isolation
Approximately 15g of placental fragments were subjected to a second digest with collagenase.
For that, tissue fragments were incubated with 50mL of 12.5U/mL collagenase I (SigmaAldrich AG, Buchs, Switzerland), 80U/mL DNase I for one hour at 37°C. Cell suspensions from both trypsin and collagen digests were filtered twice through 100µm cell strainers (BD Bioscience, San Jose, CA), then the cells were collected by centrifugation for 5min at 300g.
The cell pellets were shortly resuspend in hypotonic red blood cell lysis buffer (physiological saline with 2mm EDTA, 0.5% BSA, without Ca und Mg, diluted 1:10 with distilled water), pelleted again by 5min centrifugation at 300g. Finally, the cells were suspended in 10ml Non Hematopoietic Stem Cell Expansion Medium (NH expansion medium; Miltenyi Biotec GmBH, Bergisch-Gladbach, Germany) and plated into a single 75cm 
Antibodies
Information about primary and secondary antibodies used for flow cytometry and immunochemistry is provided in Table 2 . 
Cytogenetic analysis
Chromosome analysis of PD-MSCs cultures, passage 3, from six donors was performed.
Briefly, metaphase chromosome preparations were performed according to standard procedures at a 400-500 GTG band level. Analysis and identification of the chromosomes was performed using a Zeiss Axioplan microscope (Carl Zeiss AG, Feldbach, Switzerland).
Images were recorded with a Photometrics CCD KAF1400 camera (Photometrics, Tucson, AZ) and controlled with smart capture imaging software (Vysis, Inc., Downers Grove, IL). and syncytiotrophoblast-specific marker placental alkaline phosphatase (PLAP). 31 Curiously, the entire cell population was positive for two markers of enddifferentiated cells such as the endothelial protein vWF, and the smooth muscle cell protein α-smooth muscle actin. PD-MSCs were negative for KDR, cytokeratin 18, CD117 and CD271.
We found high levels of HLA-ABC but no HLA-DR. Both flow cytometry and immunocytochemistry revealed that part of the passage 1 cells expressed the antigen CD133 which is considered as a marker of non-committed early progenitors of blood cells, endothelial cells and other stem cell types. 32, 33 Immunocytochemistry did no detect expression of human stem cell markers of pluripotency 
Comment
In demonstrating that term human placenta, which is a readily available and ethically relatively unproblematic tissue, constitutes a robust source of MSCs, we investigated several parameters, namely (1) chromosome number, (2) origin, (3) methods of isolation and (4) propagation that are important for their principal utility for cell-based therapy, and could influence their proliferative as well as differentiation capacities. Chromosome number was found normal in all analyzed PD-MSC isolates (N=6). Looking at maternal or fetal origin, we found that PD-MSC isolates obtained with our isolation procedure were always of maternal origin, which was contrary to our expectations. This finding corroborates the very recent observation by Barlow et al., that cells isolated from placentas of male delivered babies were not of fetal origin. In contrast, the study by Fukuchi et al., which is the only investigation, reported the detection of fetal origin cells isolated from human term placenta. However, looking at the image provided in the same study, a fraction of the isolated cells was of fetal origin, while the remaining cells were of maternal origin. The precise placental anatomical origin of the maternal cells obtained with our procedure is still unclear. One source could be maternal decidua, despite our careful attempts to remove this layer completely before digestion of placenta. Placental septa constitute another potential source. One explanation for the obvious difficulty to capture fetal mesenchymal stem cells from term human placenta is offered by the fact that most of stem cells observed in the first trimester of pregnancy are differentiated to cytotrophoblast and endothelium cells in terminal and intermediate villi, while the few remaining stem cells were only detectable around the stem villi. 36, 37 Furthermore, the thinning of the stromal layer and decreased cell density towards the end of gestation is known as a positive adaptation to ensure the increasing nutritional supply of the growing fetus. 38 We think that the most likely origin of the maternal cells obtained in our study is decidual tissue that remained on placental septa, which is difficult to remove. Induction with VEGF of endothelial differentiation in early passage PD-MSCs showed that the induced cells expressed CD34, a marker for endothelial precursors. We strongly caution about an interpretation that PD-MSCs could differentiate into endothelial cells, but rather think that this finding could point to a broader plasticity of PD-MSCs.
In conclusion, we have described a highly reproducible, straightforward methodology that leads to isolation of multipotent mesenchymal stem cells of maternal origin from human term placenta. Further studies are now indicated to evaluate the properties of such maternallyderived PD-MSCs regarding their full differentiation capacity in vitro, and ultimately in vivo.
Aside from evaluating their utility for future cell replacement therapy and tissue engineering, we will seek to resolve whether such PD-MSC isolates could become exploited in transplantation medicine for an ability to exert immunosuppressive effects 41 , and/or to secret pro-angiogenic and anti-apoptotic cytokines to aid tissue healing. 
